Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Psychiatry
•
Child & Adolescent Psychiatry
•
Public & Community Psychiatry
•
General Outpatient Psychiatry
In patients with intellectual disability and persistent aggressive behaviors despite multiple antipsychotic trials, have you found pimavanserin to be a useful adjunctive treatment?
Related Questions
How do you differentiate major depressive disorder from baseline functioning in patients with intellectual disabilities?
What opportunities do you see for combining xanomeline-tropsium (Cobenfy) with other anti-psychotic agents?
What strategies have you found effective for obtaining insurance approval for xanomeline-tropsium (Cobenfy)?
How do you approach titration or transitioning to Cobenfy in patients currently on an antipsychotic?
Which patients do you think would benefit most from xanomeline-tropsium (Cobenfy) monotherapy?
What has your experience been with using SSRIs to treat negative symptoms of schizophrenia?
How do you handle requests for disability or accommodations in clinical settings with limited administrative support or documentation time?
How do you manage withdrawal symptoms after stimulant discontinuation?
What strategies do you use for patients on medications for ADHD who experience afternoon rebound/withdrawal?
When and how do you approach prescribing viloxazine for patients with ADHD?
